Compile Data Set for Download or QSAR
Report error Found 416 Enz. Inhib. hit(s) with all data for entry = 7637
TargetHistone deacetylase 6(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM50005711(GNF-Pf-1011 | CHEBI:46024 | TRICHOSTATIN | Trichos...)
Affinity DataIC50: 1.40nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM50005711(GNF-Pf-1011 | CHEBI:46024 | TRICHOSTATIN | Trichos...)
Affinity DataIC50: 6.70nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM50005711(GNF-Pf-1011 | CHEBI:46024 | TRICHOSTATIN | Trichos...)
Affinity DataIC50: 9.60nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 5(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM50005711(GNF-Pf-1011 | CHEBI:46024 | TRICHOSTATIN | Trichos...)
Affinity DataIC50: 12.5nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 2(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM50005711(GNF-Pf-1011 | CHEBI:46024 | TRICHOSTATIN | Trichos...)
Affinity DataIC50: 14.8nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207743(US9265734, R23)
Affinity DataIC50: 20nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207746(US9265734, R26)
Affinity DataIC50: 20nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207650(US9265734, R130)
Affinity DataIC50: 21nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetPolyamine deacetylase HDAC10(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM50005711(GNF-Pf-1011 | CHEBI:46024 | TRICHOSTATIN | Trichos...)
Affinity DataIC50: 22.8nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207811(US9265734, R92)
Affinity DataIC50: 26nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207744(US9265734, R24)
Affinity DataIC50: 27nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207742(US9265734, R22)
Affinity DataIC50: 28nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207705(US9265734, R185)
Affinity DataIC50: 31nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207704(BDBM207788 | US9265734, R184)
Affinity DataIC50: 31nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207815(US9265734, R96)
Affinity DataIC50: 32nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207748(US9265734, R28)
Affinity DataIC50: 32nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207789(US9265734, R70)
Affinity DataIC50: 33nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207781(US9265734, R62)
Affinity DataIC50: 33nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207703(US9265734, R183)
Affinity DataIC50: 33nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 4(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM50005711(GNF-Pf-1011 | CHEBI:46024 | TRICHOSTATIN | Trichos...)
Affinity DataIC50: 34.8nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207769(US9265734, R49)
Affinity DataIC50: 35nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207739(US9265734, R19)
Affinity DataIC50: 36nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207809(US9265734, R90)
Affinity DataIC50: 36nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207817(US9265734, R98)
Affinity DataIC50: 37nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207785(US9265734, R66)
Affinity DataIC50: 38nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207782(US9265734, R63)
Affinity DataIC50: 39nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207738(US9265734, R18)
Affinity DataIC50: 40nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207820(US9265734, R101)
Affinity DataIC50: 41nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207749(US9265734, R29)
Affinity DataIC50: 41nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207768(US9265734, R48)
Affinity DataIC50: 41nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207751(US9265734, R31)
Affinity DataIC50: 41nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207818(US9265734, R99)
Affinity DataIC50: 45nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207760(US9265734, R40)
Affinity DataIC50: 46nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207762(US9265734, R42)
Affinity DataIC50: 47nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207819(US9265734, R100)
Affinity DataIC50: 48nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207766(US9265734, R46)
Affinity DataIC50: 49nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207751(US9265734, R31)
Affinity DataIC50: 52nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207790(US9265734, R71)
Affinity DataIC50: 54nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207747(US9265734, R27)
Affinity DataIC50: 55nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207765(US9265734, R45)
Affinity DataIC50: 56nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207704(BDBM207788 | US9265734, R184)
Affinity DataIC50: 57nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207745(US9265734, R25)
Affinity DataIC50: 57nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207808(US9265734, R89)
Affinity DataIC50: 58nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207755(US9265734, R35)
Affinity DataIC50: 58nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207771(US9265734, R52)
Affinity DataIC50: 58nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207748(US9265734, R28)
Affinity DataIC50: 59nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207741(US9265734, R21)
Affinity DataIC50: 60nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207755(US9265734, R35)
Affinity DataIC50: 61nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207776(US9265734, R57)
Affinity DataIC50: 66nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207649(US9265734, R129)
Affinity DataIC50: 66nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/9/2017
Entry Details
US Patent

Displayed 1 to 50 (of 416 total ) | Next | Last >>
Jump to: